Recent BioUtah News & Events

Recursion, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021.

CenExel announces the acquisition of Advanced Memory Research Institute (“CenExel AMRI”), the largest Alzheimer’s Disease clinical research site in the Northeast. CenExel AMRI conducts Phase I through Phase IV studies, primarily in Alzheimer’s Disease, Memory Loss, and Dementia research.

U.S. Ski & Snowboard joins the growing list of professional sports organizations, including NBA and NFL teams, using R-Zero’s tech to reduce health risks from COVID-19 and other airborne and surface pathogens

BioHive on Wednesday was front and center as U.S. Representative Blake Moore (R-UT-1) toured Edwards Lifesciences, BD and Stryker – all leading medical device manufacturers in Utah that provide thousands of good-paying, stable jobs. During the visits, Moore was able to see first-hand the work that these companies do to innovate and produce life-changing technologies.  “We […]

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2021.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Global life sciences leader Cytiva has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Cytiva will use Intermountain’s manufacturing site in Utah to rapidly boost its liquid cell culture production by millions of liters. Hiring is ongoing to rapidly increase output.

ReddyPort, a medical technology company focused on bringing new non-invasive ventilation (NIV) products into market

ELITechGroup is pleased to announce the CE mark for use of saliva on SARS-CoV-2 ELITe MGB® Kit.

The second calendar quarter (2Q) of 2021 financial results were dramatically different from 2Q 2020 because 2Q 2020 results were the low point of Utah Medical Products, Inc.’s (Nasdaq: UTMD) performance during the COVID-19 pandemic, during a time when there were restrictions on so-called nonessential medical procedures. Therefore, UTMD management reports quarterly income statement results compared to the same periods not only in 2021 compared to 2020, but also compared to 2019. The Company’s stated objective in 2021 has been to try to fully recover back to its 2019 financial performance. Please see the income statements for all three years on the last page. 

CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of ForCare Clinical Research (“CenExel FCR”), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience. CenExel FCR conducts Phase I through Phase IV studies in both chronic and acute conditions, primarily in Dermatology

Biomerics LLC, a leading mid-market contract manufacturer for the interventional medical device market, announced it has acquired a majority interest in Berg Manufacturing Inc. Berg Manufacturing, based in Santa Clara, California, is an industry leader in Swiss micromachining for the advanced robotic surgery, endoscope, and interventional catheter markets.

Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans.

PolarityTE on July 28 announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE®. The trial met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) assessed at 4, 6, 8, 10, and 12 weeks. Nikolai […]

PolarityTE recently announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE’s minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology. This most recent allowance further […]

PolarityTE on Monday announced the submission of an investigational new drug application (IND) to the FDA seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. SkinTE is PolarityTE’s human cellular and tissue-based product derived from a patient’s own skin. David Seaburg, Chief Executive […]

Last week, Foldax presented on the company’s innovative Tria valve at the 2021 Transcatheter Valve Technologies (TVT) meeting. View the slides HERE. The presentation titled “Foldax Biopolymer Valves: An Alternative to Tissue Based Leaflet Valves” was given by Foldax investigator, Dr. David Heimansohn, chief of surgery at St. Vincent/Ascension in Indiana and was well received. […]

U.S. Senator Mike Lee (R-UT) on July 16 toured Stryker’s Neurovascular Division with division President, Mark Paul, joined by BioUtah President and CEO, Kelvyn Cullimore and members of the Senator’s staff. During the tour, Lee learned about the innovative, best-in-class technologies manufactured at the Salt Lake City facility to treat stroke patients. Stroke is the […]

Co-Diagnostics has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea’s Intellectual Property Office for the Company’s CoPrimer™ technology. Developed in 2013, Co-Diagnostics’ solely-owned CoPrimer technology received its first patent from the US Patent Office in 2018, and underpins the company’s molecular diagnostic test products that […]

South Salt Lake-based R-Zero, the first biosafety technology company dedicated to creating safer, healthier indoor spaces, announced July 20 its acquisition of CoWorkr, the leading property technology company offering privacy-first space utilization sensors for data-driven workplaces. Fresh off its Series B raise closed in June, R-Zero’s first acquisition accelerates speed to market for an IoT […]

Owlet on July 15 announced that it completed its business combination with Sandbridge Acquisition Corporation, a special purpose acquisition company (SPAC) as previously announced in February. Following the transaction, the company was renamed Owlet, Inc, and its Class A common stock and warrants began trading on the New York Stock Exchange under the symbols “OWLT” […]

Sera Prognostics – The Pregnancy Company® – located in Salt Lake City, Utah, has announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share. Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies […]

MMV, a Salt Lake City-based seed-stage venture capital firm, announced the first close of its second fund, MMVII. The fund will be managed by Managing Partners Branden Rosenhan, MD, Saumitra Thakur, MD and General Partner and COO Katelin Roberts. “95% of our first fund investors have joined us in MMVII, many stepping up their commitments. […]